OBJECTIVES:  While GVDs are considered a critical component of a new product’s global market access/reimbursement plan, anecdotal evidence suggests variability across organizations in perceptions of purpose and utility. METHODS:  A web-based survey was fielded to global and regional employees of pharmaceutical manufacturers with responsibility in developing and/or executing market access strategy for new products. RESULTS:  A total of 42 industry employees participated in the survey; regions represented included Europe, North America, and Asia-Pacific. The perceived primary purposes of a GVD were to assist in preparing local health technology assessment (HTA) submissions and/or provide comprehensive disease state and product review (73%); 20% felt the primary purpose was to highlight product value. However, only 50% of respondents indicated that the GVD adequately addressed their purposes. Only 23 of 36 respondents who have developed a local HTA submission reported having a GVD “the last time” they prepared/reviewed a local HTA submission, and only 31% (n=7/23) felt the GVD provided value. Greatest barriers to use were lack of relevancy to country/region (57%), lack of comprehensive content (39%), language (English) (35%), and cumbersome format (30%). Of elements commonly included in GVDs, those most important for local HTA submissions were clinical efficacy (95%), epidemiology (87%), unmet needs (87%), and product description (76%). In comparison, cost-effectiveness (21%) and budget impact (11%) were deemed the least important. Utility of these sections is likely driven by specific country HTA/reimbursement schema, although the sample size was too small to draw meaningful conclusions. Most respondents indicated the most useful time to have a GVD was 6-12 months pre-approval (65%); 20% would prefer earlier (2+ years pre-approval). CONCLUSIONS: One of the greatest challenges with GVDs is balancing comprehensiveness with specificity. Opportunity for improvement remains in the timely provision of valuable data to affiliates responsible for local HTA submissions.